Company overview. Lonza Group AG (commonly "Lonza"; the entity also appears in English-language filings as Lonza Group Ltd) is a Swiss multinational headquartered at Münchensteinerstrasse 38, Basel, Switzerland. Founded in 1897, it is publicly listed on the SIX Swiss Exchange (ticker LONN) and is a Swiss Market Index constituent, with a secondary listing on the SGX Singapore Exchange and an OTC ADR (LZAGY). It is not a subsidiary. Lonza reports roughly 20,000 employees across more than 30 sites on five continents. FY2025 group sales were CHF 6.5 billion with CORE EBITDA of CHF 2.1 billion; market capitalization has recently been in the CHF 37–40 billion range. It describes itself today as a pure-play CDMO.
Products / services. Lonza is a contract development and manufacturing organization serving pharmaceutical and biotech customers — the counterpart to a drug developer, not a seller of branded medicines. Activities are organized in three platforms: Integrated Biologics (mammalian cell culture, drug substance, aseptic drug product fill-finish), Advanced Synthesis (small molecules, highly potent APIs, bioconjugates including antibody-drug-conjugate components), and Specialized Modalities (cell and gene therapies, mRNA, microbial and nucleic-acid platforms). Its former Specialty Ingredients segment, covering microbial control and personal-care ingredients, was divested in 2022.
Patent-litigation posture. This is an operating company, not an NPE or shell licensor. The tracked data show one case with Lonza as plaintiff and none as defendant. The single offensive suit is nearly two decades old and reflects enforcement of internally developed gene-expression technology rather than a licensing campaign; nothing in the record indicates a recurring assertion program or a plaintiff-friendly venue pattern (the case sits in the District of Maryland, not the Eastern District of Texas).
Notable case. Lonza Group AG v. Northwest Biotherapeutics, Inc. (D. Md., filed Nov. 27, 2007) alleged infringement of Lonza gene-expression patents by Northwest's DCVax products. Lonza had first filed in the District of Delaware earlier in 2007; after Northwest relocated to Bethesda, Maryland, that case was dismissed and refiled in Maryland. Lonza filed an amended complaint in December 2007 narrowing the accusations to DCVax-Prostate. The outcome is not documented in the tracked data.